NCT01058616 - Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Cancer With Transdermal Accessible Tumour

Interventions

DRUG

LTX-315 (Oncopore™)

5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.

Trial Locations (2)

0310

Oslo University Hospital, Radiumhospitalet, Oslo

171 76

Karolinska University Hospital, Solna, Stockholm